Trade-Ideas: Incyte (INCY) Is Today's Post-Market Leader Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Trade-Ideas LLC identified Incyte (INCY) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Incyte as such a stock due to the following factors:
- INCY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $69.6 million.
- INCY is up 2.3% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in INCY with the Ticky from Trade-Ideas. See the FREE profile for INCY NOW at Trade-IdeasMore details on INCY: Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Currently there are 11 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.The average volume for Incyte has been 1.7 million shares per day over the past 30 days. Incyte has a market cap of $5.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.58 and a short float of 9.3% with 4.30 days to cover. Shares are up 117% year to date as of the close of trading on Friday.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.TheStreetRatings.com Analysis:TheStreet Quant Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and feeble growth in its earnings per share.Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 163.7% when compared to the same quarter one year ago, falling from $4.04 million to -$2.57 million.
- The gross profit margin for INCYTE CORP is rather low; currently it is at 24.95%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -2.52% is significantly below that of the industry average.
- Net operating cash flow has declined marginally to $8.08 million or 7.37% when compared to the same quarter last year. Despite a decrease in cash flow INCYTE CORP is still fairing well by exceeding its industry average cash flow growth rate of -19.71%.
- INCYTE CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, INCYTE CORP continued to lose money by earning -$0.36 versus -$1.48 in the prior year. For the next year, the market is expecting a contraction of 2.8% in earnings (-$0.37 versus -$0.36).
- Compared to its closing price of one year ago, INCY's share price has jumped by 115.70%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in INCY do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Incyte Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV